Ocugen Inc OCGN
News
Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
Ocugen Gets FDA Clearance for IND Amendment for OCU400
Ocugen's stock climbs as it beats back investor claims on COVID vaccine